Imatinib mesylate in the treatment of chronic myeloid leukaemia

By Druker Brian J  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. : 963-971

Informa Healthcare

Access to resources Recommend Favorite

Effects of Imatinib Mesylate on Renin–Angiotensin System (RAS) Activity During the Clinical Course of Chronic Myeloid Leukaemia

By Sayitoglu M   Haznedaroğlu IC   Hatirnaz O   Erbilgin Y   Aksu S   Koca E   Adiguzel C   Bayik M   Akalin I   Gülbas Z   Akay M   Unal A   Kaynar L   Ovali E   Yilmaz M   Yenerel M   Dagdas S   Ozet G   Ar C   Aydin Y   Soysal T   Durgun B   Ozcebe O   Tukun A   Ilhan O   Ozbek U  

The Journal of International Medical Research, Vol. 37, Iss. 4, 2009-07 ,pp. : 1018-1028

Field House Publishing

Access to resources Recommend Favorite

Imatinib mesylate-resistant cells were present in a man with chronic myeloid leukaemia (CML) before treatment with the drug

By  

Inpharma, Vol. 1, Iss. 1390, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Dasatinib Treatment for Imatinib Resistant or Intolerant Patients with Chronic Myeloid Leukaemia

By Li J   Xu G   Yu S   He L   Guo L  

The Journal of International Medical Research, Vol. 39, Iss. 2, 2011-03 ,pp. : 337-347

Field House Publishing

Access to resources Recommend Favorite

AstraZeneca's lung cancer agent gefitinib [`Iressa'] is being launched at a 25% discount to the chronic myeloid leukaemia agent imatinib mesylate

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 412, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite